-
1.发明授权Amino substituted pyridinyl methanone compounds useful in treating kinase disorders 有权用于治疗激酶障碍的氨基取代的吡啶酮甲酮化合物公开(公告)号：US07109220B2
公开(公告)日：2006-09-19
申请号：US10981087
申请日：2004-11-04
Applicant: Ronghui Lin , Steven K. Wetter , Yanhua Lu , Peter J. Connolly , Stuart Emanuel , Robert H. Gruninger , Steven A. Middleton
Inventor： Ronghui Lin , Steven K. Wetter , Yanhua Lu , Peter J. Connolly , Stuart Emanuel , Robert H. Gruninger , Steven A. Middleton
IPC: A61K31/44 , C07D213/60
CPC classification number: C07D213/73 , C07D213/74 , C07D213/75 , C07D405/06 , C07D409/06
Abstract: The present invention provides amino substituted pyridinyl methanone compounds; pharmaceutical compositions comprising the compounds and methods of synthesis thereof. The compounds, which are cyclin dependent kinase (CDK) inhibitors, can be used to treat or ameliorate CDK mediated disorders. The invention thus also provides the therapeutic or prophylactic use of the compounds and/or pharmaceutical compositions to treat such disorders.
Abstract translation: 本发明提供氨基取代的吡啶基甲酮化合物; 包含该化合物的药物组合物及其合成方法。 作为细胞周期蛋白依赖性激酶（CDK）抑制剂的化合物可用于治疗或改善CDK介导的病症。 因此，本发明还提供了治疗或预防性使用化合物和/或药物组合物来治疗这些疾病。
-
2.发明申请Amino substituted pyridinyl methanone compounds useful in treating kinase disorders 有权用于治疗激酶障碍的氨基取代的吡啶酮甲酮化合物公开(公告)号：US20050124610A1
公开(公告)日：2005-06-09
申请号：US10981087
申请日：2004-11-04
Applicant: Ronghui Lin , Steven Wetter , Yanhua Lu , Peter Connolly , Stuart Emanuel , Robert Gruninger , Steven Middleton
Inventor： Ronghui Lin , Steven Wetter , Yanhua Lu , Peter Connolly , Stuart Emanuel , Robert Gruninger , Steven Middleton
IPC: A61K31/44 , A61K31/443 , A61K31/4436 , A61K31/4439 , A61K31/444 , C07D213/72 , C07D213/73 , C07D213/74 , C07D213/75 , C07D401/02 , C07D405/02 , C07D405/06 , C07D409/02 , C07D409/06 , C07D413/02 , C07D417/02 , C07D43/02
CPC classification number: C07D213/73 , C07D213/74 , C07D213/75 , C07D405/06 , C07D409/06
Abstract: The present invention provides amino substituted pyridinyl methanone compounds; pharmaceutical compositions comprising the compounds and methods of synthesis thereof. The compounds, which are cyclin dependent kinase (CDK) inhibitors, can be used to treat or ameliorate CDK mediated disorders. The invention thus also provides the therapeutic or prophylactic use of the compounds and/or pharmaceutical compositions to treat such disorders.
Abstract translation: 本发明提供氨基取代的吡啶基甲酮化合物; 包含该化合物的药物组合物及其合成方法。 作为细胞周期蛋白依赖性激酶（CDK）抑制剂的化合物可用于治疗或改善CDK介导的病症。 因此，本发明还提供了治疗或预防性使用化合物和/或药物组合物来治疗这些疾病。
-
公开(公告)号：USD696096S1
公开(公告)日：2013-12-24
申请号：US29402387
申请日：2011-09-22
Applicant: Stuart Emanuel Daneman
Designer： Stuart Emanuel Daneman
-
公开(公告)号：US08524244B2
公开(公告)日：2013-09-03
申请号：US12867406
申请日：2009-02-10
Applicant: Ray Camphausen , Brent Morse , Stuart Emanuel , David Fabrizio
Inventor： Ray Camphausen , Brent Morse , Stuart Emanuel , David Fabrizio
IPC: A61K38/17 , A61K38/39 , A61K47/48 , C07K14/71 , C07K14/435
CPC classification number: C07K14/78 , A61K38/00 , C07K14/765 , C07K14/79 , C07K16/2863 , C07K19/00 , C07K2317/31 , C07K2318/20 , C07K2319/30
Abstract: The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
Abstract translation: 本发明涉及结合表皮生长因子受体（EGFR）的单结构域蛋白。 本发明还涉及用于诊断，研究和治疗应用的单结构域蛋白。 本发明还涉及包含这种蛋白质的细胞，编码这种蛋白质或其片段的多核苷酸，以及包含编码该创新蛋白质的多核苷酸的载体。
-
公开(公告)号：US08314234B2
公开(公告)日：2012-11-20
申请号：US11858609
申请日：2007-09-20
Applicant: Peter J. Connolly , Stuart Emanuel , Ronghui Lin , Yanhua Lu , Steven A. Middleton
Inventor： Peter J. Connolly , Stuart Emanuel , Ronghui Lin , Yanhua Lu , Steven A. Middleton
IPC: C07D487/04 , A61K31/519 , A61P35/00 , A61P17/00 , A61P25/28
CPC classification number: C07D487/04 , C07D498/04
Abstract: The present invention is directed to novel bicyclic pyrimidine compounds of Formula (I) or a form or composition thereof and the use thereof as inhibitors of ATP-protein kinase interactions.
Abstract translation: 本发明涉及式（I）的新型双环嘧啶化合物或其形式或组合物及其作为ATP-蛋白激酶相互作用抑制剂的用途。
-
Patent Agency Ranking
公开(公告)号：US20110053842A1
公开(公告)日：2011-03-03
申请号：US12867406
申请日：2009-02-10
Applicant: Ray Camphausen , Brent Morse , Stuart Emanuel , David Fabrizio
Inventor： Ray Camphausen , Brent Morse , Stuart Emanuel , David Fabrizio
CPC classification number: C07K14/78 , A61K38/00 , C07K14/765 , C07K14/79 , C07K16/2863 , C07K19/00 , C07K2317/31 , C07K2318/20 , C07K2319/30
Abstract: The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
Abstract translation: 本发明涉及结合表皮生长因子受体（EGFR）的单结构域蛋白。 本发明还涉及用于诊断，研究和治疗应用的单结构域蛋白。 本发明还涉及包含这种蛋白质的细胞，编码这种蛋白质或其片段的多核苷酸，以及包含编码该创新蛋白质的多核苷酸的载体。
-
公开(公告)号：US20100179094A1
公开(公告)日：2010-07-15
申请号：US12625217
申请日：2009-11-24
Applicant: Stuart Emanuel , Linda Engle , Ray Camphausen , Martin C. Wright , Ginger Chao , Marco Gottardis , Joan Carboni
Inventor： Stuart Emanuel , Linda Engle , Ray Camphausen , Martin C. Wright , Ginger Chao , Marco Gottardis , Joan Carboni
CPC classification number: C07K14/78 , A61K38/39 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K14/475 , C07K16/2863 , C07K2317/31 , C07K2317/34 , C07K2317/92 , C07K2318/20 , C07K2319/30
Abstract: The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.
Abstract translation: 本发明涉及包含EGFR结合结构域和用于诊断，研究和治疗应用的不同IGFIR结合结构域的双特异性分子。 本发明还涉及包含这种蛋白质的细胞，编码这种蛋白质或其片段的多核苷酸，以及包含编码创新蛋白质的多核苷酸的载体。 示例性双特异性分子包括基于第十纤连蛋白III型结构域的抗体样蛋白二聚体。
-
公开(公告)号：US09145188B1
公开(公告)日：2015-09-29
申请号：US13737742
申请日：2013-01-09
Applicant: Stuart Emanuel Daneman
Inventor： Stuart Emanuel Daneman
Abstract: A mount extending the reach of a shallow water anchoring system, which includes a block mounting device with two open-ended and spaced-apart longitudinally-extending bores each having at least two smaller threaded bores with interior ends that are in communication with the longitudinal bores. Preferably, the smaller threaded bores are spaced apart and aligned in a row, and also have perpendicular orientation to the longitudinal bore. The extendable anchoring pole of a shallow water anchoring system is secured within one of the longitudinal bores via fasteners, while an independent rod longer than the anchoring pole is secured via fasteners within the other longitudinal bore, wherein the independent rod can be vertically deployed into a sea bottom adjacent to a boat at water depths exceeding the anchoring system's intended reach. A small stabilizer block with similar bores spaced apart from the mount further stabilizes the pole and independent rod during anchoring use.
Abstract translation: 延伸到浅水锚定系统的延伸部的安装座，其包括具有两个开放和间隔开的纵向延伸的孔的块安装装置，每个孔具有至少两个较小的螺纹孔，其内端与纵向孔连通 。 优选地，较小的螺纹孔被间隔开并且排列成一排，并且还具有与纵向孔的垂直取向。 浅水锚固系统的可伸缩锚杆通过紧固件固定在一个纵向孔内，而长于锚固杆的独立杆通过紧固件固定在另一个纵向孔内，其中独立杆可以垂直部署成 海底毗邻船舶，水深超过锚固系统的预期距离。 具有与安装座间隔开的相似孔的小的稳定器块进一步在锚固使用期间稳定杆和独立的杆。
-
公开(公告)号：US07541367B2
公开(公告)日：2009-06-02
申请号：US11443994
申请日：2006-05-31
Applicant: George Chiu , Peter J. Connolly , Stuart Emanuel , Shenlin Huang , Shengjian Li , Ronghui Lin , Yanhua Lu , Steven A. Middleton
Inventor： George Chiu , Peter J. Connolly , Stuart Emanuel , Shenlin Huang , Shengjian Li , Ronghui Lin , Yanhua Lu , Steven A. Middleton
IPC: A01N43/42 , A61K31/44 , C07D471/02 , C07D491/02 , C07D498/02 , C07D513/02 , C07D515/02
CPC classification number: C07D471/04
Abstract: The present invention is directed to novel 3-benzoimidazolyl-pyrazolopyridine compounds of formula (I): and pharmaceutically acceptable forms thereof and their synthesis and use as inhibitors of serine-threonine protein kinases and tyrosine protein kinases and interactions thereof.
-
公开(公告)号：US20070270425A1
公开(公告)日：2007-11-22
申请号：US11609450
申请日：2006-12-12
Applicant: Guozhang Xu , Lily Lee , Terry Hughes , Steven Wetter , Peter Connolly , Marta Abad , Stuart Emanuel , Prabha Karnachi , Steven Middleton
Inventor： Guozhang Xu , Lily Lee , Terry Hughes , Steven Wetter , Peter Connolly , Marta Abad , Stuart Emanuel , Prabha Karnachi , Steven Middleton
IPC: A61K31/5377 , A61P43/00 , C07D239/48 , C07D413/02
CPC classification number: C07D239/48 , C07D401/12 , C07D403/12 , C07D407/12 , C07D413/04 , C07D417/12
Abstract: The present invention is directed to substituted pyrimidine compounds of formula (I): and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.
Abstract translation: 本发明涉及式（I）的取代嘧啶化合物及其形式，其合成和用途，用于治疗，预防或改善慢性或急性蛋白激酶介导的疾病，病症或病症。
-
-
-
-
-
-
-
-
-
Search Results
23
records
(took 0.024 seconds)
